Skip to main content
. Author manuscript; available in PMC: 2010 Nov 8.
Published in final edited form as: Cancer Gene Ther. 2007 Dec 14;15(2):115–125. doi: 10.1038/sj.cgt.7701110

Figure 6. Early or delayed treatment (day 30) with vvDD in the absence of 5-FC resulted in reduced tumor burden and improved survival in an immunocompetent murine ovarian tumor model.

Figure 6

(a). C57BL/6 mice were injected with 7.5 × 106 MOSEC cells to allow for growth of peritoneal ovarian tumors. Early treatment (day 0) consisted of 1.0 × 109 pfu of vvDD-CD in order to overcome the immunocompetent nature of the mice (p < 1.0 × 10e-5; control vs. vvDD-CD). (b). The delayed treatment mode (virus administration on day 30) revealed that vvDD-CD was also effective (p< 8.0 × 10e-6; control vs. vvDD-CD). (c). The physical appearance of representative control and vvDD-CD treated mice (day 80) in the delayed treatment model.